Stent-retriever based mechanical thrombectomy (MT) has gained wide acceptance as the treatment of choice for acute ischaemic stroke (AIS) caused by large vessel occlusion (LVO). The Embotrap 3 is the latest iteration within this class of device. We present our results using the new Embotrap 3 device. Materials and Methods We performed a retrospective review of our prospectively maintained database to identify all patients treated with the Embotrap 3 stent-retriever between January 2021 and January 2022. We recorded the baseline demographics, NIHSS, ASPECT score and clot characteristics, first pass and final eTICI scores, complications and 90 day mRS. Results One hundred and ten patients met the inclusion criteria, average age 69 ± 14 years, 50% were male ( n = 55). The median NIHSS at presentation was 18 (range 3–30) and 58.2% received IV tPA prior to MT. The median ASPECT score on plain CT was 8 with average clot length 20.2 ± 14.8 mm ( n = 93). The first pass effect (FPE) was seen in 41.8% of cases with modified FPE seen in 59.1%. A 24-hour CT scan ( n = 97) showed median ASPECTs of 7. 43.8% of patients achieve mRS ≤ 2 at 90-day mRS ( n = 64). Conclusion The Embotrap 3 stent-retriever has a high rate of FPE and final recanalization in this real world cohort of patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.